Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

UPB

Upstream Bio Inc

May 01 • 10:19AM ET

9.24

+0.06 0.65 %

Healthcare • Biotechnology • USA • Small • NASD

Held by: VTI IWM VXF IWN IBB SCHA VTWO FFSM DFAS VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.66	Insider Own	46.75%	Shs Outstand	54.24M	Perf Week	-0.65%
Market Cap	502.85M	Forward P/E	-	EPS next Y	-3.16	Insider Trans	-0.02%	Shs Float	28.98M	Perf Month	-0.75%
Enterprise Value	162.61M	PEG	-	EPS next Q	-0.74	Inst Own	72.44%	Short Float	10.43%	Perf Quarter	-70.27%
Income	-143.44M	P/S	176.44	EPS this Y	-8.62%	Inst Trans	6.36%	Short Ratio	2.34	Perf Half Y	-61.80%
Sales	2.85M	P/B	1.47	EPS next Y	-9.42%	ROA	-34.34%	Short Interest	3.02M	Perf YTD	-65.97%
Book/sh	6.26	P/C	1.47	EPS next 5Y	-11.20%	ROE	-35.43%	52W High	33.68 -72.57%	Perf Year	2.67%
Cash/sh	6.28	P/FCF	-	EPS past 3/5Y	-81.53% -	ROIC	-42.15%	52W Low	7.25 27.45%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	33.04% -	Gross Margin	93.41%	Volatility	4.17% 5.37%	Perf 5Y	-
Dividend TTM	-	EV/Sales	57.05	EPS Y/Y TTM	-	Oper. Margin	-5618.82%	ATR (14)	0.56	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	26.15	Sales Y/Y TTM	-	Profit Margin	-5026.03%	RSI (14)	42.51	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	26.15	EPS Q/Q	-93.28%	SMA20	-5.19%	Beta	1.29	Target Price	45.20
Payout	-	Debt/Eq	0.00	Sales Q/Q	8.97%	SMA50	2.42%	Rel Volume	0.20	Prev Close	9.18
Employees	75	LT Debt/Eq	0.00	Earnings	Mar 26 BMO	SMA200	-51.04%	Avg Volume	1.29M	Price	9.24
IPO	Oct 11, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.53% 14.38%	Trades		Volume	42,969	Change	0.65%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-26	Downgrade	Evercore ISI	Outperform → In-line	$15
Dec-18-25	Initiated	Mizuho	Outperform	$51
Nov-18-25	Initiated	Evercore ISI	Outperform	$40
Oct-14-25	Initiated	Truist	Buy	$47
Nov-05-24	Initiated	William Blair	Outperform
Nov-05-24	Initiated	TD Cowen	Buy
Nov-05-24	Initiated	Piper Sandler	Overweight	$75
Nov-05-24	Initiated	JP Morgan	Overweight	$38

Apr-17-26 07:00AM	Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference (GlobeNewswire)
Mar-27-26 09:46AM	Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls (The Fly) -11.44%
Mar-26-26 07:00AM	Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-01-26 09:45AM	Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting (GlobeNewswire)
Feb-26-26 07:00AM	Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 (GlobeNewswire)
07:00AM	Loading…
Feb-25-26 07:00AM	Upstream Bio to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-15-26 07:11PM	Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56% (MarketBeat)
Feb-13-26 10:45AM	Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns (Benzinga) -31.64%
Feb-12-26 07:55AM	Upstream Bios stock drops 47% on verekitug Phase II asthma data (Clinical Trials Arena) -12.87%
Feb-11-26 09:57AM	Upstream Bio Crashes After Asthma Drug Succeeds - With The Wrong Dose (Investor's Business Daily) -47.18%
09:02AM	Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts (Benzinga)
06:00AM	Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma (GlobeNewswire)
04:33AM	Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill (BioPharma Dive)
Feb-10-26 06:00PM	Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma (GlobeNewswire) +6.47%
Jan-05-26 07:00AM	Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
07:00AM	Loading…
Nov-25-25 07:00AM	Upstream Bio to Participate in Upcoming December Investor Conferences (GlobeNewswire) +10.67%
Nov-05-25 07:00AM	Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress (GlobeNewswire)
Oct-31-25 07:00AM	Upstream Bio to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-16-25 04:33PM	Upstream Bio Presents New Structural Data on Verekitug, Highlights Unique TSLP Receptor Targeting (Insider Monkey) -5.88%
Sep-30-25 04:15AM	Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress (GlobeNewswire) +8.48%
Sep-16-25 01:59PM	Upstream Bio, Inc. (UPB): A Bull Case Theory (Insider Monkey)
Sep-09-25 07:00AM	Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Sep-02-25 06:00AM	Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (GlobeNewswire) +18.27%
Sep-01-25 05:00PM	Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (GlobeNewswire)
Aug-20-25 12:13AM	Upstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, Verekitug (Insider Monkey)
Aug-06-25 07:00AM	Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress (GlobeNewswire) +7.87%
Jul-09-25 09:00AM	First subject dosed in Upstream Bios Phase II trial of verekitug for COPD (Clinical Trials Arena) +7.34%
Jul-08-25 07:00AM	Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) (GlobeNewswire)
Jun-15-25 07:45AM	Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor (GlobeNewswire)
Jun-05-25 07:00AM	Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 (GlobeNewswire)
07:00AM	Loading…
Jun-04-25 07:00AM	Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-20-25 07:00AM	Upstream Bio Appoints Stacy Price as Chief Technology Officer (GlobeNewswire)
May-06-25 07:00AM	Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs (GlobeNewswire) -5.41%
Apr-17-25 05:51PM	Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent (Seeking Alpha) +10.59%
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-12-25 07:00AM	Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +7.83%
Feb-25-25 08:00AM	Upstream Bio to Present at Upcoming March Investor Conferences (GlobeNewswire) -5.96%
Feb-11-25 09:00AM	Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps (PR Newswire)
Jan-06-25 08:00AM	Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.47%
Dec-17-24 08:00AM	Upstream Bio Appoints Allison Ambrose as General Counsel (GlobeNewswire)
Dec-16-24 08:00AM	Upstream Bio Announces Addition to Russell 2000 Index (GlobeNewswire) -6.12%
Nov-21-24 08:00AM	Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-08-24 07:11AM	Upstream Bio reports Q3 revenue $607,000 vs $621,000 last year (TipRanks)
Nov-07-24 07:00AM	Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-17-24 07:02PM	Orbimed Advisors LLC Acquires New Stake in Upstream Bio Inc (GuruFocus.com) +9.66%
Oct-15-24 04:15PM	Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +6.27%
Oct-10-24 07:35PM	Upstream Bio Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GRAY MICHAEL	CFO and COO	Mar 16 '26	Sale	9.29	852	7,915	29,648	Mar 17 05:03 PM
Deykin Aaron	Chief Medical Officer	Mar 16 '26	Sale	9.29	894	8,305	32,687	Mar 17 05:02 PM
Sutherland Everett Rand	Chief Executive Officer	Mar 16 '26	Sale	9.29	2,093	19,444	72,907	Mar 17 05:00 PM
Ambrose Allison	General Counsel	Mar 16 '26	Sale	9.29	475	4,413	16,525	Mar 17 05:00 PM
Houghton Adam	Chief Business Officer	Mar 16 '26	Sale	9.29	699	6,494	24,301	Mar 17 04:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UPB

Upstream Bio Inc

Upgrade your Finviz experience